



Research article

Evaluation of clinicopathological abnormalities in sick cats naturally infected by *Leishmania infantum*

Manolis K. Chatzis^{a,*}, Panagiotis G. Xenoulis^a, Leonidas Leontides^b, Dimitrios Kasabalis^a, Mathios E. Mylonakis^c, Margarita Andreadou^d, John Ikononopoulos^d, Manolis N. Saridomichelakis^a

^a Clinic of Medicine, Faculty of Veterinary Science, University of Thessaly, 224 Trikalon Str., GR-43132, Karditsa, Greece

^b Laboratory of Epidemiology, Biostatistics and Animal Health Economics, Faculty of Veterinary Science, University of Thessaly, 224 Trikalon Str., GR-43132, Karditsa, Greece

^c Companion Animal Clinic, School of Veterinary Medicine, Aristotle University of Thessaloniki, 11 Stavrou Voutyra Str., GR-54627, Thessaloniki, Greece

^d Department of Anatomy and Physiology of Farm Animals, Faculty of Animal Science, Agricultural University of Athens, 75 Iera Odos, Votanikos, GR-11855, Athens, Greece

ARTICLE INFO

Keywords:

CAT
Clinicopathological abnormalities
Leishmania infantum
Phosphorus
Kidney disease
Parasite
Leishmania
Veterinary medicine
Infectious disease
Parasitology

ABSTRACT

Feline infection by *Leishmania infantum* (syn. *L. chagasi*) has been described in areas where canine leishmaniosis is endemic. A wide variety of clinicopathological abnormalities have been reported in cats presenting clinical signs of leishmaniosis but there is a paucity of information regarding cats infected by *L. infantum* that do not suffer from leishmaniosis but from other diseases. The aim of this study was to compare: a) the frequency of clinicopathological abnormalities and b) the values of hematology, serum biochemistry and urinalysis parameters, between non-infected sick cats and sick cats that were infected by *L. infantum*. A total of 50 cats with cutaneous, ocular and/or systemic clinical signs that lived in an endemic area and had been tested for infection by *L. infantum* using PCR from four different tissues, were included. Based on the results of PCR, 20/50 cats were found to be infected and 30/50 non-infected. The only difference between the two groups of cats was that the concentration of inorganic phosphorus ($P = 0.043$) was higher in infected cats. This finding may suggest an association between infection by *L. infantum* and feline kidney disease.

1. Introduction

Feline infection by *Leishmania infantum* (syn. *L. chagasi*) has been described in areas where canine leishmaniosis is endemic, including several European (Pennisi et al., 2013; Vilhena et al., 2013; Chatzis et al., 2014; Migliazzo et al., 2015; Persichetti et al., 2016; Spada et al., 2016; Otranto et al., 2017), Latin American (Benassi et al., 2017; Metzendorf et al., 2017), and Asian (Hatam et al., 2010; Akhtardanesh et al., 2017) countries. Most infected cats remain healthy, possibly because of their natural resistance to the disease (Solano-Gallego et al., 2007; Pennisi et al., 2013). Only a minority of them develop leishmaniosis and they present a variety of skin lesions, ocular and/or systemic signs (Pennisi et al., 2004; Vita et al., 2005; Marcos et al., 2009; Vides et al., 2011; Sobrinho et al., 2012; Pennisi et al., 2013; Metzendorf et al., 2017; Fernandez-Gallego et al., 2020). However, not all clinical signs of cats with leishmaniosis are necessarily due to this disease, some may be caused by

comorbidities. Clinical findings and pathologies that could be reliably attributed to feline leishmaniosis, based on the presence of the parasite and/or of compatible histologic lesions in affected tissues and organs, include skin ulcers and nodules, conjunctivitis, keratitis, uveitis, peripheral lymphadenomegaly, splenomegaly, hepatomegaly, rhinitis, ulcerative stomatitis and chronic kidney disease due to glomerulonephritis and/or interstitial nephritis (Marcos et al., 2009; Hatam et al., 2010; Sobrinho et al., 2012; Pennisi et al., 2013; Migliazzo et al., 2015; Metzendorf et al., 2017). We have previously reported a positive association between infection by *L. infantum* and the presence of at least one systemic (but not cutaneous or ocular) clinical sign that has been reported in cats with leishmaniosis (Chatzis et al., 2014).

Numerous clinicopathological abnormalities such as anemia, leukocytosis or leukopenia, neutrophilia or neutropenia, lymphocytosis or lymphopenia, monocytosis, thrombocytopenia, increased total protein and globulin concentrations, azotemia, increased alkaline phosphatase

* Corresponding author.

E-mail address: mchatzis@vet.uth.gr (M.K. Chatzis).

<https://doi.org/10.1016/j.heliyon.2020.e05177>

Received 10 June 2020; Received in revised form 1 August 2020; Accepted 3 October 2020

2405-8440/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

(ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) activities, proteinuria, bilirubinuria and hematuria have been reported in cats with leishmaniosis, without always being clear whether they are caused by the disease or by comorbidities (Pennisi et al., 2004; Rufenacht et al., 2005; Vita et al., 2005; Paludo et al., 2008; Marcos et al., 2009; Pennisi et al., 2013; Akhtardanesh et al., 2017; Fernandez-Gallego et al., 2020). The only clinicopathological abnormality that appears to be directly associated with this disease is hyperglobulinemia, which is usually polyclonal and is caused by increased alpha 2-, beta- and/or gamma-globulins (Pennisi et al., 2004; Marcos et al., 2009).

Based on the combined results of blood, skin, bone marrow and conjunctiva PCR, we have previously reported that 20/50 (40%) of the cats that lived in an endemic area and presented various cutaneous, ocular and/or systemic clinical signs, were positive for *L. infantum* DNA, although none were diagnosed with leishmaniosis (Chatzis et al., 2014). The aim of the present study was to compare a) the frequency of clinicopathological abnormalities and b) the values of hematology, serum biochemistry and urinalysis parameters between these 20 infected and the 30 non-infected cats.

2. Materials and methods

2.1. Study population and PCR

A total of 50 cats living in Central and Northern, Greece, where canine leishmaniosis due to *L. infantum* is endemic (Leontides et al., 2002; Athanasiou et al., 2012), were included. Handling of these animals was in compliance with European Communities Council Directive 86/609/EEC and state laws. The experimental protocol had been approved by State Authorities (license Nr. 3698/31-10-08).

Details of inclusion and exclusion criteria, sampling and PCR have been previously published (Chatzis et al., 2014). Briefly, all cats were at least 1-year old with no history of leishmaniosis or administration of drugs with known anti-*Leishmania* or immune-modulating activity. Conventional PCR (Andreadou et al., 2012) in blood, skin biopsies, bone marrow and conjunctiva swabs was performed to differentiate infected from non-infected cats (Chatzis et al., 2014).

2.2. Sample collection

For cats less than 8 years-old without systemic clinical signs, chemical restraint was induced by intramuscular administration of a combination of ketamine (5 mg/kg body weight; Ketaset®, Fort Dodge Animal Health, Iowa, USA), midazolam (0.2 mg/kg body weight; Dormicum®, Roche Hellas, Athens, Greece) and dexmedetomidine (20 µg/kg body weight; Dexdomitor®, Zoetis, New Jersey, USA). In older cats and/or those with systemic disease, the dose of dexmedetomidine was reduced (5 µg/kg body weight) and butorphanol (0.2–0.4 mg/kg body weight; Butomidor®, Richter Pharma, Austria) was added to the drug combination.

Blood samples were collected via jugular venipuncture using a 21 G needle attached to a Monovette® syringe (Sarstedt G & Co; Germany). Approximately 10 ml of blood was collected: 2 ml were immediately transferred into EDTA tubes and the remaining was left to clot for 20 min and was centrifuged at 3,000 rpm for 20 min to harvest the serum. Urine samples were collected with cystocentesis: urinalysis, including sediment microscopy after centrifugation at 1,500 rpm for 5 min, was performed within 1 h, and an aliquot was stored at -20 °C until measurement of urine protein/creatinine ratio (UP/C). Urine samples were cultured for the detection of aerobic bacteria if there was evidence of infection.

2.3. Clinicopathological examinations

Complete blood count was performed using the VetAutoread™ Hematology Analyzer (IDEXX Laboratories, Westbrook, MA) followed by a manual 100-cell leucocyte differential count on a Giemsa-stained blood smear. Serum concentration of total proteins, albumin, blood urea

nitrogen, creatinine, glucose, cholesterol, total bilirubin, calcium, inorganic phosphorus, and activities of ALP, ALT, AST, gamma-glutamyl transferase (GGT) and creatine kinase were measured using the Vet-Test® Chemistry Analyzer (IDEXX Laboratories, Westbrook, MA). The concentration of globulins was calculated by subtracting albumin from the total protein concentration, and subsequently the albumin/globulin ratio was also calculated. Additionally, serum potassium, sodium and chloride concentrations were measured using the VetStat® Electrolyte and Blood Gas Analyzer (IDEXX Laboratories, Westbrook, MA).

Urinalysis included the measurement of specific gravity with a refractometer (American Optical), dipstick examination (Multistix® 10 SG, Bayer), microscopic examination of sediment and calculation of the UP/C ratio (for those samples without evidence of hematuria or urinary tract infection). Urine protein concentration was determined by the pyrogallol red-molybdate method (Watanabe et al., 1986) with a spectrophotometer (Shimadzu, UV-1601), using commercially available reagents (Urinary Proteins LR®, Cesan). Urine creatinine concentration was determined by the colorimetric kinetic method (Romeo, 1975) with the same spectrophotometer, using commercially available reagents (Creatinine Kinetic®, Flowcytogen Laboratories). Cats were classified as non-proteinuric, borderline-proteinuric, or proteinuric when the UP/C ratio was <0.2, ≥0.2 and ≤0.4, or >0.4, respectively (Elliott, 2007).

2.4. Statistical analysis

In the initial univariable screening, the frequency of clinicopathological abnormalities was compared between infected and non-infected cats, by either Pearson's χ^2 or Fisher's exact test. Subsequently, the normality of the distributions of the concentration or activity of serum biochemistry parameters was tested by the Kolmogorov-Smirnov test. The parameters which did not deviate from normality are presented as means \pm standard deviation and were compared between infected and non-infected cats by independent sample t-tests. The parameters whose distributions deviated from normality are presented as medians and range and were compared between infected and non-infected cats by the Mann Whitney U test.

Variables that were significantly different ($P \leq 0.25$) between infected and non-infected cats in the univariable screening of the frequency of clinicopathological abnormalities or in the univariable comparison of the distributions of the concentration or activity of serum and urine biochemistry parameters, were selected as initial candidates for two separate logistic regression models using stepwise, forward, and backward selection procedures. Variables identified as being associated with the infection status of the cat (at $P < 0.05$) were retained in the final models. Odds ratios (OR) derived from the models were interpreted as measures of increased risk of infection. Because infection was not a rare condition in the study population, the OR were not precise measures of increased risk, but the approximation was reasonable and was utilized to clarify the presentation of results. The goodness of fit of the models was evaluated using the Hosmer-Lemeshow goodness-of-fit chi-square statistic with the data divided into 4 groups. The analyses were done in Stata 13 (Stata Corp, College Station, TX).

3. Results

Details on the signalment and the final diagnoses of the cats included in the present study have been previously published (Chatzis et al., 2014).

The frequency of the abnormalities found in hematology, serum biochemistry and urinalysis are presented in Table 1 and the values of the clinicopathological parameters in Table 2. The most common abnormalities were hyperglycemia (24/50-48%) and increased creatine kinase activity (30/50–60%), but, in the majority of the cases, they were attributed to the stress plus dexmedetomidine administration and to the intramuscular injection of the sedative agents, respectively. Urine samples were obtained from 42/50 (84%) cats. Specific gravity and pH

Table 1. Comparison of the prevalence of abnormalities found in hematology, serum biochemistry and urinalysis in 50 cats with cutaneous, ocular and/or systemic clinical signs, including 20 cats naturally infected by *L. infantum* and 30 non-infected cats.

Laboratory abnormality	Infected; n = 20 (%)	Non-infected; n = 30 (%)	P value
Hematology			
↓ PCV	4 (20%)	7 (23.3%)	1
↓ Hemoglobin	4 (20%)	7 (23.3%)	1
↓ White blood cells	0 (0%)	2 (6.7%)	0.51
↑ White blood cells	7 (35%)	6 (20%)	0.236
↑ Neutrophils	7 (35%)	8 (26.7%)	0.529
↑ Band neutrophils	6 (30%)	4 (13.3%)	0.171
↓ Lymphocytes	6 (30%)	12 (40%)	0.47
↑ Lymphocytes	1 (5%)	3 (10%)	0.641
↑ Monocytes	2 (10%)	2 (6.7%)	1
↑ Eosinophils	0 (0%)	1 (3.3%)	1
↓ Platelets	2 (10%)	1 (3.3%)	0.556
Serum biochemistry			
↓ Total proteins	3 (15%)	5 (16.7%)	1
↓ Albumins	2 (10%)	3 (10%)	1
↓ Globulins	2 (10%)	1 (3.3%)	0.556
↑ Globulins	1 (5%)	1 (3.3%)	1
↓ A/G ratio	3 (15%)	2 (6.7%)	0.377
↑ A/G ratio	0 (0%)	1 (3.3%)	1
↑ Urea nitrogen	5 (25%)	4 (13.3%)	0.454
↑ Creatinine	3 (15%)	0 (0%)	0.058
↓ Glucose	1 (5%)	2 (6.7%)	1
↑ Glucose	9 (45%)	15 (50%)	0.729
↓ Cholesterol	1 (5%)	1 (3.3%)	1
↑ Cholesterol	1 (5%)	0 (0%)	0.4
↑ Total bilirubin	5 (25%)	1 (3.3%)	0.032
↑ ALP	5 (25%)	1 (3.3%)	0.032
↑ ALT	4 (20%)	2 (6.7%)	0.202
↑ AST	5 (25%)	4 (13.3%)	0.454
↑ GGT	3 (15%)	0 (0%)	0.058
↑ Creatine kinase	12 (60%)	18 (60%)	1
↓ Calcium	3 (15%)	2 (6.7%)	0.377
↓ Inorganic phosphorus	0 (0%)	2 (6.7%)	0.51
↑ Inorganic phosphorus	3 (15%)	0 (0%)	0.058
↓ Potassium	1 (5%)	1 (3.3%)	1
↑ Potassium	3 (15%)	2 (6.7%)	0.377
↓ Sodium	3 (15%)	2 (6.7%)	0.377
↑ Sodium	0 (0%)	1 (3.3%)	1
↓ Chloride	1 (5%)	1 (3.3%)	1
↑ Chloride	2 (10%)	2 (6.7%)	1
Urinalysis			
↑ UP/C ratio	3/12 (25%)	5/22 (22.7%)	1

A/G: albumins/globulins; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; PCV: packed cell volume; UP/C: urine protein/creatinine.

ranged from 1.001 to 1.040 (median: 1.031) and from 6 to 8 (median: 6), respectively. Glycosuria was present in 7/42 (16.7%) cats and was accompanied by hyperglycemia in six of them. Ketonuria was found in one (2.4%) cat diagnosed with diabetes mellitus and bilirubinuria in 2/42 (4.8%) cats and was accompanied by increased serum total bilirubin concentration. Also, 5/42 (11.9%) cats had hematuria due to idiopathic cystitis (2/5–40%) or urinary tract infection (3/5–60%). Three additional cats had urinary tract infection without hematuria and the UP/C ratio was determined in 34/50 (68%) cats. It ranged from 0.09 to 1.5 (median: 0.23) and proteinuria (UP/C ratio >0.4) was detected in 8/34 (23.5%) cats.

In the univariable screening, the frequency of increased total bilirubin concentration and increased ALP activity was significantly higher in infected cats (Table 1) but in the final logistic regression model, none was

associated with the cat's infection status. Absolute neutrophil count, GGT activity and inorganic phosphorus concentration were significantly higher in infected compared to non-infected cats (Table 2) but in the final logistic model only increased inorganic phosphorus concentration retained significance ($P = 0.043$; OR = 1.82, 95% CI: 1.02–3.23). The Hosmer–Lemeshow goodness-of-fit χ^2 statistic for this model, did not show evidence of lack-of-fit (Hosmer–Lemeshow $\chi^2 = 1.70$, $P = 0.43$).

4. Discussion

In general, cats are considered resistant to infection by *L. infantum* (Pennisi et al., 2013). However, some infected cats develop clinical signs and/or clinicopathological abnormalities of leishmaniosis (Pennisi et al., 2013). The lack of significant differences in the frequency of

Table 2. Comparison of the values of hematology, serum biochemistry and urinalysis parameters in 50 cats with cutaneous, ocular and/or systemic clinical signs, including 20 cats naturally infected by *L. infantum* and 30 non-infected cats.

Parameter (units)	Infected (n = 20)	Non-infected (n = 30)	P value
Hematology			
PCV (%)	31.7 ± 11.4*	30 ± 8.7	0.559
Hemoglobin (g/dl)	10.2 ± 3.4	9.6 ± 2.6	0.457
White blood cells (/μl)	17,230 ± 8,726.9	12,873.3 ± 10,181.2	0.125
Neutrophils (/μl)	10,934 (5,141–28,251)**	7,353 (3,358–46,550)	0.024
Band neutrophils (/μl)	136 (0–5,346)	49 (0–1,527)	0.453
Lymphocytes (/μl)	2,394.5 (159–10,062)	1,818.4 (574–8,653)	0.259
Monocytes (/μl)	266 (0–990)	97 (0–1,900)	0.196
Eosinophils (/μl)	148.5 (0–1,420)	132 (0–1,527)	0.848
Platelets (/μl)	338,650 ± 147,237.1	387,466.7 ± 151,668.8	0.265
Serum biochemistry			
Total proteins (g/dl)	6.8 ± 1.1	6.6 ± 1	0.503
Albumins (g/dl)	2.9 ± 0.6	2.8 ± 0.5	0.868
Globulins (g/dl)	4 ± 0.9	3.8 ± 0.7	0.357
A/G ratio	0.7 ± 0.2	0.8 ± 0.2	0.573
Urea nitrogen (mg/dl)	19 (3–130)	22 (12–75)	0.451
Creatinine (mg/dl)	1.1 (0.4–15)	1.4 (0.6–1.9)	0.442
Glucose (mg/dl)	186.7 ± 113.4	171.4 ± 83.7	0.586
Cholesterol (mg/dl)	131.8 ± 59.5	128.1 ± 33.6	0.778
Total bilirubin (mg/dl)	0.4 (0.1–6.5)	0.2 (0.1–1.3)	0.177
ALP (U/l)	53 (21–262)	35.5 (10–130)	0.073
ALT (U/l)	57 (15–429)	35.5 (12–600)	0.242
AST (U/l)	22.5 (9–260)	22 (1–87)	0.721
GGT (U/l)	0 (0–4)	0 (0–0)	0.03
Creatine kinase (U/l)	423.9 ± 269.5	456.4 ± 355.8	0.729
Calcium (mg/dl)	8.9 ± 1.2	9.3 ± 1.2	0.189
Inorganic phosphorus (mg/dl)	5.7 (4–16.1)	4.8 (2.9–7.1)	0.014
Potassium (mmol/l)	5.1 (1.5–9)	4.8 (3.2–6.5)	0.197
Sodium (mmol/l)	159 (140–165)	161 (148–166)	0.193
Chloride (mmol/l)	122 (108–160)	122 (111–160)	0.796
Urinalysis			
UP/C ratio	0.3 ± 0.2	0.3 ± 0.3	0.937

A/G: albumins/globulins; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; PCV: packed cell volume; UP/C: urine protein/creatinine.

* Parameters with normal distribution are presented as mean ± standard deviation.

** Parameters that significantly deviate from normality are presented as medians and range.

hematological abnormalities between infected and non-infected cats, along with the results of a previous study (Paludo et al., 2008), suggests that infection by *L. infantum* is not accompanied by hematological abnormalities commonly reported in cats with leishmaniosis, such as anemia, leukocytosis, leukopenia, neutrophilia, neutropenia, lymphopenia, thrombocytopenia and pancytopenia (Pennisi et al., 2004; Rufenacht et al., 2005; Marcos et al., 2009; da Silva et al., 2010; Pennisi et al., 2013) or that these abnormalities occur in a minority of infected cats and are obscured by the hematological abnormalities due to their primary diseases.

Increased serum concentrations of inorganic phosphorus and creatinine were observed in none of the 30 non-infected cats and in 3/20 infected cats, including two cats with acute kidney injury due to urethral obstruction and one cat with chronic kidney disease (Tuzio, 2001; Javadi et al., 2005; Kidder and Chew, 2009; Segev et al., 2011). Although this difference was not significant in the final logistic regression model, the increased concentration of inorganic phosphorus was. Kidney lesions, similar to those of canine leishmaniosis (Plevraki et al., 2006; Marcos et al., 2009), have been reported in cats with the disease (e.g. glomerulonephritis and interstitial nephritis with granulomatous inflammation) and increased serum creatinine concentration is not uncommon in feline leishmaniosis (Pennisi et al., 2004; Marcos et al., 2009). Subsequently, in few infected cats, *L. infantum* may contribute to the pathogenesis of

kidney disease. However, this finding should be interpreted with caution, since other parameters of kidney function (especially serum creatinine concentration and UP/C ratio) did not differ between the infected and non-infected cats.

5. Conclusions

In conclusion, *L. infantum* infection, not only did not lead to symptoms of the disease (Chatzis et al., 2014), but also was not associated with laboratory abnormalities other than increased serum inorganic phosphorus concentration. Further studies are needed to determine the biological significance of this finding by investigating if parasite antigen, immune complexes and mononuclear inflammatory cells are present in the kidneys of infected cats, similarly to what is observed in asymptomatic dogs infected by *L. infantum* (Esch et al., 2015).

Declarations

Author contribution statement

Manolis K. Chatzis: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Panagiotis G. Xenoulis, Margarita Andreadou, John Ikonopoulos: Performed the experiments; Contributed reagents, materials, analysis tools or data.

Leonidas Leontides: Analyzed and interpreted the data.

Dimitrios Kasabalis: Contributed reagents, materials, analysis tools or data.

Mathios E. Mylonakis: Performed the experiments.

Manolis N. Saridomichelakis: Conceived and designed the experiments; Analyzed and interpreted the data.

Funding statement

This research has been co-financed by the European Union (European Social Fund-ESF) and Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF)-Research Funding Program: Heraclitus II investing in knowledge society through the European Social Fund. The funding source was not involved in the study design, collection, analysis and interpretation of data, writing of the report or the decision to submit the article for publication.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

- Akhtardanesh, B., Sharifi, I., Mohammadi, A., Mostafavi, M., Hakimmipour, M., Pourafshar, N.G., 2017. Feline visceral leishmaniasis in Kerman, southeast of Iran: serological and molecular study. *J. Vector Borne Dis.* 54, 96–102.
- Andreadou, M., Liandris, E., Kasampalidis, I.N., Taka, S., Antoniou, M., Ntais, P., Vaiopoulou, A., Theodoropoulos, G., Gazouli, M., Ikonopoulos, J., 2012. Evaluation of the performance of selected in-house and commercially available PCR and real-time PCR assays for the detection of *Leishmania* DNA in canine clinical samples. *Exp. Parasitol.* 131, 419–424.
- Athanasio, L.V., Kontos, V.I., Saridomichelakis, M.N., Rallis, T.S., Diakou, A., 2012. A cross-sectional sero-epidemiological study of canine leishmaniasis in Greek mainland. *Acta Trop.* 122, 291–295.
- Benassi, J.C., Benvenega, G.U., Ferreira, H.L., Pereira, V.F., Keid, L.B., Soares, R., Oliveira, T., 2017. Detection of *Leishmania infantum* DNA in conjunctival swabs of cats by quantitative real-time PCR. *Exp. Parasitol.* 177, 93–97.
- Chatzis, M.K., Andreadou, M., Leontides, L., Kasabalis, D., Mylonakis, M., Koutinas, A.F., Rallis, T., Ikonopoulos, J., Saridomichelakis, M.N., 2014. Cytological and molecular detection of *Leishmania infantum* in different tissues of clinically normal and sick cats. *Vet. Parasitol.* 202, 217–225.
- da Silva, S.M., Rabelo, P.F., Gontijo Nde, F., Ribeiro, R.R., Melo, M.N., Ribeiro, V.M., Michalick, M.S., 2010. First report of infection of *Lutzomyia longipalpis* by *Leishmania (Leishmania) infantum* from a naturally infected cat of Brazil. *Vet. Parasitol.* 174, 150–154.
- Elliott, J., 2007. Staging chronic kidney disease. In: Elliott, J., Grauer, F. (Eds.), *BSAVA Manual of Canine and Feline Nephrology and Urology*. British Small Animal Association, Gloucester UK, pp. 159–166.
- Esch, K.J., Schaut, R.G., Lamb, I.M., Clay, G., Lima, Á.L.M., do Nascimento, P.R.P., Whitley, E.M., Jeronimo, S.M.B., Sutterwala, F.S., Haynes, J.S., Petersen, C.A., 2015. Activation of autophagy and nucleotide-binding domain leucine-rich repeat-containing-like receptor family, pyrin domain-containing 3 inflammasome during *Leishmania infantum*-associated glomerulonephritis. *Am. J. Pathol.* 185, 2105–2117.
- Fernandez-Gallego, A., Feo Bernabe, L., Dalmau, A., Esteban-Saltiveri, D., Font, A., Leiva, M., Ortúñez-Navarro, A., Peña, M.T., Tabar, M.D., Real-Sampietro, L., Saló, F., Lloret, A., Bardagi, M., 2020. Feline leishmaniasis: diagnosis, treatment and outcome in 16 cats. *J. Feline Med. Surg.*
- Hatam, G.R., Adnani, S.J., Asgari, Q., Fallah, E., Motazedian, M.H., Sadjjadi, S.M., Sarkari, B., 2010. First report of natural infection in cats with *Leishmania infantum* in Iran. *Vector Borne Zoonotic Dis.* 10, 313–316.
- Javadi, S., Djajadiningrat-Laanen, S.C., Kooistra, H.S., van Dongen, A.M., Voorhout, G., van Sluijs, F.J., van den Ingh, T.S., Boer, W.H., Rijnberk, A., 2005. Primary hyperaldosteronism, a mediator of progressive renal disease in cats. *Domest. Anim. Endocrinol.* 28, 85–104.
- Kidder, A.C., Chew, D., 2009. Treatment options for hyperphosphatemia in feline CKD: what's out there? *J. Feline Med. Surg.* 11, 913–924.
- Leontides, L.S., Saridomichelakis, M.N., Billinis, C., Kontos, V., Koutinas, A.F., Galatos, A.D., Mylonakis, M.E., 2002. A cross-sectional study of *Leishmania* spp. infection in clinically healthy dogs with polymerase chain reaction and serology in Greece. *Vet. Parasitol.* 109, 19–27.
- Marcos, R., Santos, M., Malhao, F., Pereira, R., Fernandes, A.C., Montenegro, L., Roccabianca, P., 2009. Pancytopenia in a cat with visceral leishmaniasis. *Vet. Clin. Pathol.* 38, 201–205.
- Metzdorf, I.P., da Costa Lima, M.S.J., de Fatima Cepa Matos, M., de Souza Filho, A.F., de Souza Tsujisaki, R.A., Franco, K.G., Shapiro, J.T., de Almeida Borges, F., 2017. Molecular characterization of *Leishmania infantum* in domestic cats in a region of Brazil endemic for human and canine visceral leishmaniasis. *Acta Trop.* 166, 121–125.
- Migliazzo, A., Vitale, F., Calderone, S., Puleio, R., Binanti, D., Abramo, F., 2015. Feline leishmaniasis: a case with a high parasitic burden. *Vet. Dermatol.* 26, 69–70.
- Otranto, D., Napoli, E., Latrofa, M.S., Annoscia, G., Tarallo, V.D., Greco, G., Lorusso, E., Gulotta, L., Falsone, L., Basano, F.S., Pennisi, M.G., Deuster, K., Capelli, G., Dantas-Torres, F., Brianti, E., 2017. Feline and canine leishmaniasis and other vector-borne diseases in the Aeolian Islands: pathogen and vector circulation in a confined environment. *Vet. Parasitol.* 236, 144–151.
- Paludo, G.R., Marodin, N.B., Firmino, F.P., Marcola, T.G., Silva, L.G., Ramos, R.R., Borges, T.S., Carranza-Tamayo, C.O., 2008. In: Occurrence of *Leishmania* Infections in Cats from an Endemic Area of Brasilia, Brazil., 13th I.S.A.C.P., 10th E.S.V.C.P., 8th A.E.C.C.P., 7th A.P.P. Congress. Barcelona, Spain, pp. 120–121.
- Pennisi, M.G., Hartmann, K., Lloret, A., Addie, D., Belak, S., Boucraut-Baralon, C., Egberink, H., Frymus, T., Gruffydd-Jones, T., Hosie, M.J., Lutz, H., Marsilio, F., Mostl, K., Radford, A.D., Thiry, E., Truyen, U., Horzinek, M.C., 2013. Leishmaniasis in cats: ABCD guidelines on prevention and management. *J. Feline Med. Surg.* 15, 638–642.
- Pennisi, M.G., Venza, M., Reale, S., Vitale, F., Lo Giudice, S., 2004. Case report of leishmaniasis in four cats. *Vet. Res. Commun.* 28 (Suppl 1), 363–366.
- Persichetti, M.F., Solano-Gallego, L., Serrano, L., Altet, L., Reale, S., Masucci, M., Pennisi, M.G., 2016. Detection of vector-borne pathogens in cats and their ectoparasites in southern Italy. *Parasites Vectors* 9, 247.
- Plevraki, K., Koutinas, A.F., Kaldrymidou, H., Roupies, N., Papazoglou, L.G., Saridomichelakis, M.N., Savvas, I., Leontides, L., 2006. Effects of allopurinol treatment on the progression of chronic nephritis in Canine leishmaniasis (*Leishmania infantum*). *J. Vet. Intern. Med.* 20, 228–233.
- Romeo, J., 1975. Evaluation of a kinetic method for creatinine. *Lab. Med.* 6, 15–18.
- Rufenacht, S., Sager, H., Muller, N., Schaerer, V., Heier, A., Welle, M.M., Roosje, P.J., 2005. Two cases of feline leishmaniasis in Switzerland. *Vet. Rec.* 156, 542–545.
- Segev, G., Livne, H., Ranen, E., Lavy, E., 2011. Urethral obstruction in cats: predisposing factors, clinical, clinicopathological characteristics and prognosis. *J. Feline Med. Surg.* 13, 101–108.
- Sobrinho, L.S., Rossi, C.N., Vides, J.P., Braga, E.T., Gomes, A.A., de Lima, V.M., Perri, S.H., Generoso, D., Langoni, H., Leutenegger, C., Biondo, A.W., Laurenti, M.D., Marcondes, M., 2012. Coinfection of *Leishmania chagasi* with *Toxoplasma gondii*, feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) in cats from an endemic area of zoonotic visceral leishmaniasis. *Vet. Parasitol.* 187, 302–306.
- Solano-Gallego, L., Rodriguez-Cortes, A., Iniesta, L., Quintana, J., Pastor, J., Espada, Y., Portus, M., Alberola, J., 2007. Cross-sectional serosurvey of feline leishmaniasis in ecoregions around the Northwestern Mediterranean. *Am. J. Trop. Med. Hyg.* 76, 676–680.
- Spada, E., Canzi, I., Baggiani, L., Perego, R., Vitale, F., Migliazzo, A., Proverbio, D., 2016. Prevalence of *Leishmania infantum* and co-infections in stray cats in northern Italy. *Comp. Immunol. Microbiol. Infect. Dis.* 45, 53–58.
- Tuzio, H.T., 2001. Acute and chronic renal failure. In: Lappin, M.R. (Ed.), *Feline Internal Medicine Secrets*. Hanley & Belfus, Philadelphia, pp. 183–202.
- Vides, J.P., Schwardt, T.F., Sobrinho, L.S., Marinho, M., Laurenti, M.D., Biondo, A.W., Leutenegger, C., Marcondes, M., 2011. *Leishmania chagasi* infection in cats with dermatologic lesions from an endemic area of visceral leishmaniasis in Brazil. *Vet. Parasitol.* 178, 22–28.
- Vilhena, H., Martinez-Diaz, V.L., Cardoso, L., Vieira, L., Altet, L., Francino, O., Pastor, J., Silvestre-Ferreira, A.C., 2013. Feline vector-borne pathogens in the north and centre of Portugal. *Parasites Vectors* 6, 99.
- Vita, S., Santori, D., Aguzzi, I., Petrotta, E., Luciani, A., 2005. Feline leishmaniasis and ehrlichiosis: serological investigation in Abruzzo region. *Vet. Res. Commun.* 29 (Suppl 2), 319–321.
- Watanabe, N., Kamei, S., Ohkubo, A., Yamanaka, M., Ohsawa, S., Makino, K., Tokuda, K., 1986. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. *Clin. Chem.* 32, 1551–1554.